Squarepoint
ALNY icon

Squarepoint’s Alnylam Pharmaceuticals ALNY Stock Holding History

Squarepoint’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.9M Sell
69,100
-4,000
-5% -$1.36M 0.03% 633
2025
Q4 		$29.1M Buy
73,100
+55,200
+308% +$24.4M 0.03% 587
2025
Q3 		$8.16M Buy
17,900
+15,400
+616% +$6.27M 0.01% 1180
2025
Q2 		$815K Buy
2,500
+400
+19% +$111K ﹤0.01% 2841
2025
Q1 		$567K Sell
2,100
-21,200
-91% -$5.45M ﹤0.01% 3177
2024
Q4 		$5.48M Buy
23,300
+15,200
+188% +$4M 0.01% 1560
2024
Q3 		$2.23M Buy
+8,100
New +$2.11M ﹤0.01% 1990
2024
Q2 		– Sell
-20,000
Closed -$2.99M – 4011
2024
Q1 		$2.99M Buy
+20,000
New +$3.34M 0.01% 1827
2021
Q2 		– Sell
-13,200
Closed -$1.86M – 3188
2021
Q1 		$1.86M Buy
+13,200
New +$1.99M 0.01% 1113

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Squarepoint's ALNY Position: Q1 2026 in Review

Squarepoint increased its Alnylam Pharmaceuticals (ALNY) stake by 22% in Q1 2026, buying an estimated $25.8M and bringing the position to 426,723 shares worth $141M. The position accounts for 0.17% of the portfolio, ranked #100.

Squarepoint first reported a position in ALNY in Q4 2015 and has held it in 33 quarters since. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Squarepoint held 426,723 shares of Alnylam Pharmaceuticals worth $141M as of Q1 2026.
  • Squarepoint bought 75,754 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $25.8M.
  • Alnylam Pharmaceuticals made up 0.17% of Squarepoint's portfolio in Q1 2026, its #100 holding.
  • Squarepoint first reported a position in Alnylam Pharmaceuticals in Q4 2015 and has held it in 33 quarters since.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.